Day: October 24, 2021

A statement on behalf of Loretta Rogers, Melinda Rogers-Hixon, Martha Rogers, John A. MacDonald, John Clappison, David Peterson, Bonnie Brooks, and Ellis Jacob

A statement on behalf of Loretta Rogers, Melinda Rogers-Hixon, Martha Rogers, John A. MacDonald, John Clappison, David Peterson, Bonnie Brooks, and Ellis Jacob

TORONTO, Oct. 24, 2021 (GLOBE NEWSWIRE) — We unequivocally support Joe Natale as CEO and support his management team. We along with the Management continue to work tirelessly on behalf of all stakeholders including customers, employees, and shareholders. We remain as duly elected members of the Rogers Communications Inc. Board and represent the majority of the Board members of the company. No other group of individuals has any authority to purport to act as the Board of Directors of Rogers Communications Inc.  About RogersRogers is a proud Canadian company dedicated to making more possible for Canadians each and every day. Our founder, Ted Rogers, purchased his first radio station, CHFI, in 1960. We have grown to become a leading technology and media company that strives to provide the very best in wireless, residential, sports,...

Continue reading

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting

REDWOOD CITY, Calif., Oct. 24, 2021 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of six poster presentations at the upcoming American College of Gastroenterology (ACG) Annual Scientific Meeting. The presentations will take place during the ACG Annual Meeting being held in Las Vegas, Nev. and virtually Oct 22 to 27, 2021. Access to all accepted ePosters and ePresentations will be available on the ACG program website and in the October online supplement to the American Journal of Gastroenterology. EG and/or EoD Prevalence Data Presentations: Title(Presenter): Endoscopy and Systematic Biopsy of Patients With Moderate-Severe Unexplained Gastrointestinal Symptoms...

Continue reading

Kvika banki hf.: Kvika to acquire majority share in Ortus Secured Finance Ltd.

Kvika banki hf.: Kvika to acquire majority share in Ortus Secured Finance Ltd.

Kvika banki hf. (“Kvika”) has agreed heads of terms with the shareholders and the management team of Ortus Secured Finance Ltd. (“Ortus”) to acquire a majority shareholding in Ortus. Ortus is a British alternative credit provider specialising in property backed lending to borrowers in the United Kingdom. The company was founded in 2013 and currently manages a 23 billion ISK equivalent private credit portfolio, of which 14.5 billion ISK is held on Ortus’ own balance sheet. If the transaction proceeds, Kvika group’s total consolidated assets are expected to grow by 10%. Ortus’ headquarters are in London and the company also operates offices in Belfast, N-Ireland and in Glasgow, Scotland. Since its launch in 2013, Ortus has advanced over 70 billion ISK equivalent to borrowers whilst experiencing no losses of capital. Kvika, through its subsidiary...

Continue reading

Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting

Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting

Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical Research Phase 1 population PK data abstract concludes the large body of pre-existing clinical data related to vonoprazan in Asian populations can be reliably applied to non-Asian populations Real-world physician and patient-based Study of Acid-Related Disorders (SOARD) provides perceptions of disease burden and highlights unmet needs in the treatment of H. pylori and erosive esophagitis FLORHAM PARK, N.J., Oct. 24, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today data from the PHALCON-HP Phase 3 study, the largest...

Continue reading

AEROMEXICO AIMS HIGHER WITH SUSTAINABLE  AVIATION FUEL FLIGHTS

AEROMEXICO AIMS HIGHER WITH SUSTAINABLE AVIATION FUEL FLIGHTS

Mexico City, Oct. 24, 2021 (GLOBE NEWSWIRE) — • There will be three operations from San Francisco during the pilot phase. • These flights will reduce 27 tons of CO2 emissions. Mexico City, October 24, 2021.- As part of the International Day of Climate Action, Aeromexico will be operating its first flights between the U.S. and Mexico with sustainable aviation fuel (SAF), reducing 27 tons of CO2 emissions, equivalent to making more than 3,800 cars zero-emission for one day in Mexico City.   The flights will depart from San Francisco to Guadalajara and Mexico City, and they will be served in a Boeing 737-800 aircraft with GE/Safran CFM56 engines. For these trips, almost 40,000 liters of sustainable fuel made from waste animal fats and vegetable oils, as well as Jet-A jet fuel, were purchased. As the beginning of a long-term partnership,...

Continue reading

Proton Therapy contract finalized with Advocate Radiation Oncology Affiliate in Florida 

Proton Therapy contract finalized with Advocate Radiation Oncology Affiliate in Florida 

           Louvain-La-Neuve, Belgium, October 24, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that its proton therapy contract with Advocate Radiation Oncology, via its affiliate Southwest Florida Proton, has been finalized. IBA will start to recognize revenue from the contract in 2021. The finalization of the contract follows the announcement earlier in the year that IBA had been selected by Advocate Radiation Oncology for its new radiation oncology center. The site will serve the greater population of Southwest Florida in a centralized location between Lee and Collier County. The contract involves the delivery of IBA’s Proteus®ONE* solution including Pencil Beam Scanning...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.